# Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

> **NCT06593392** · PHASE2 · RECRUITING · sponsor: **Vifor Fresenius Medical Care Renal Pharma** · enrollment: 18 (estimated)

## Conditions studied

- Pruritus
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Difelikefalin

## Key facts

- **NCT ID:** NCT06593392
- **Lead sponsor:** Vifor Fresenius Medical Care Renal Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-13
- **Primary completion:** 2029-08-15
- **Final completion:** 2029-08-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593392, "Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06593392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*